Core Viewpoint - Backblaze, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a negative report from Morpheus Research that highlighted financial missteps and questionable accounting practices [1][2]. Group 1: Investigation and Legal Actions - Bragar Eagel & Squire, P.C. is investigating potential claims against Backblaze on behalf of its stockholders [1]. - The investigation is focused on whether Backblaze has engaged in unlawful business practices and violated federal securities laws [1]. - Stockholders who have suffered losses or have information regarding these claims are encouraged to contact the law firm [3]. Group 2: Financial Performance and Market Reaction - Backblaze's stock experienced a significant decline following the release of a critical report from Morpheus Research, which detailed alleged financial missteps since the company's IPO in November 2021 [2]. - The report accused Backblaze of questionable accounting practices, including financial manipulations and inflated forecasts [2]. - The stock price dropped during intraday trading on April 24, 2025, in response to the report [2].

Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate Second Major Transaction in Six Months Undertaken Without Stockholder Input with Significant Equity Dilution Company's Shifting Narrative on APX3330 in Disclosures Raises Questions of Omissions, Consistency, and Integrity of Strategic Communications FDA-Approved RYZUMVI™ Received Minimal Valuation in Both the Merger and Financing Transactions Desp ...

WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full f ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of ...